Editas Medicine (EDIT)
(Real Time Quote from BATS)
$5.51 USD
-0.24 (-4.17%)
Updated Jun 5, 2024 02:57 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EDIT 5.51 -0.24(-4.17%)
Will EDIT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EDIT
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Other News for EDIT
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (EDIT)
Editas Medicine: Promising Milestone Achieved But Be Patient
Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June